Zuora's share price shows recent improvement, possibly indicating a positive business shift. Yet, its long-term performance, a roughly 9% annual loss over five years, is more significant. Three warning signs with Zuora should be considered in investment decisions.
祖睿股票讨论
向上 ⬆️⬆️⬆️⬆️⬆️
当今的公司正在寻求更高水平的业务灵活性,以部署新的业务模式、推出产品线并在国际上扩张。同时,他们需要自己的应用程序和平台来帮助他们扩展到首次公开募股及以后。这些新的集成解决方案将为财务团队提供更大的灵活性,增强的订阅分析,并使部署和采用两位企业领导者的技术比以往任何时候都更容易。
$VIZIO(VZIO.US)$
$Fulgent Genetics(FLGT.US)$
$Cara Therapeutics(CARA.US)$
$KnowBe4, Inc.(KNBE.US)$
$Coursera(COUR.US)$
$Intellia Therapeutics(NTLA.US)$
$Natera(NTRA.US)$
$DraftKings(DKNG.US)$
$Natural Alternatives International(NAII.US)$
$Revolve Group(RVLV.US)$
$A10 Networks(ATEN.US)$
$祖睿(ZUO.US)$
Insider Buying
$Spero Therapeutics(SPRO.US)$
$Lumos Pharma(LUMO.US)$
$Oscar Health(OSCR.US)$
$Phibro Animal Health(PAHC.US)$
暂无评论